JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal ...
11/01/2025

Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, with additive effects observed when combined with high-risk drugs. https://ja.ma/4oDBeVa

Both combined and progestin-only contraceptives are linked to increased breast cancer risk, with greater risk observed f...
10/31/2025

Both combined and progestin-only contraceptives are linked to increased breast cancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. https://ja.ma/49lee8P

10/30/2025

🎧 Listen to authors Yiwen Zhang, PhD, and Edward L. Giovannucci, MD, ScD discuss their article "Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality," with Vivek Subbiah, MD. https://ja.ma/3J1QKv0

💬 Editorial: Consistent long-term physical activity—about 17 metabolic equivalent task-hours/week over 30 years—was link...
10/30/2025

💬 Editorial: Consistent long-term physical activity—about 17 metabolic equivalent task-hours/week over 30 years—was linked to optimally reduced risk of digestive system cancers. https://ja.ma/47e7JUc

Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with o...
10/30/2025

Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. https://ja.ma/47tbC6u

Glucagon-like peptide-1 receptor agonists ( ) are associated with a reduced overall risk in adults with , lowering th...
10/29/2025

Glucagon-like peptide-1 receptor agonists ( ) are associated with a reduced overall risk in adults with , lowering the risk for endometrial, ovarian, and meningioma cancers, while potentially increasing the risk for kidney cancer. https://ja.ma/4oJzz0p

Cisplatin treatment decreased kidney function, with lower baseline eGFR patients at higher CKD risk, and a pretreatment ...
10/28/2025

Cisplatin treatment decreased kidney function, with lower baseline eGFR patients at higher CKD risk, and a pretreatment eGFR-based model effectively predicted this risk for clinical use. https://ja.ma/4hrgWfb

Public awareness of , its vaccine, and its links is low in the US, especially in the Midwest and South, contributing ...
10/27/2025

Public awareness of , its vaccine, and its links is low in the US, especially in the Midwest and South, contributing to suboptimal vaccination rates in these regions. https://ja.ma/3L7Re3a

Sintilimab plus axitinib shows a promising objective response rate and progression-free survival with a manageable safet...
10/26/2025

Sintilimab plus axitinib shows a promising objective response rate and progression-free survival with a manageable safety profile for patients with advanced fumarate hydratase–deficient renal cell carcinoma. https://ja.ma/3WhWXWH

Dexrazoxane use in pediatric AML rose from 0.5% to 98.5% between 2010 and 2021, coinciding with a 50% reduction in ICU-l...
10/24/2025

Dexrazoxane use in pediatric AML rose from 0.5% to 98.5% between 2010 and 2021, coinciding with a 50% reduction in ICU-level cardiovascular care, supporting rapid adoption of dexrazoxane for cardioprotection with intensive chemotherapy. https://ja.ma/3L9ytwe

Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting m...
10/23/2025

Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting most survivors benefit from primary care focused on prevention and management of traditional cardiovascular risk factors rather than routine long-term specialist surveillance.

https://ja.ma/4hus8b4

A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-s...
10/23/2025

A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis.

https://ja.ma/3JpPwtu

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category